Lisa Peraza's Insider Trades & SAST Disclosures
Lisa Peraza's most recent trade in Heron Therapeutics Inc was a trade of 41,078 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 19, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Lisa Peraza.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 41,078 | 41,078 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Peraza Lisa | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 6,846 | 6,846 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 1,289 | 56,663 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Peraza Lisa | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 1,289 | 6,675 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Peraza Lisa | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.15 per share. | 13 Jan 2024 | 756 | 55,907 (0%) | 0% | 2.1 | 1,625 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 552 | 55,374 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Peraza Lisa | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 552 | 1,656 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2023 | 150,000 | 150,000 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2023 | 1,933 | 26,170 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2023 | 1,933 | 9,896 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.31 per share. | 13 Jul 2023 | 860 | 25,310 (0%) | 0% | 1.3 | 1,127 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2023 | 552 | 2,760 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2023 | 552 | 24,237 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 1,932 | 11,829 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 1,932 | 24,545 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. | 13 Apr 2023 | 860 | 23,685 (0%) | 0% | 2.9 | 2,477 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 552 | 22,613 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 552 | 3,312 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 42,631 | 42,631 | - | - | Performance Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 1,933 | 13,761 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 1,933 | 23,074 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. | 13 Jan 2023 | 1,013 | 22,061 (0%) | 0% | 3.2 | 3,211 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 552 | 3,864 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 552 | 21,141 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,932 | 15,694 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,932 | 21,450 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. | 13 Oct 2022 | 861 | 20,589 (0%) | 0% | 3.8 | 3,237 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 553 | 19,518 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 553 | 4,416 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 60,902 | 60,902 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,933 | 17,626 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,933 | 19,825 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. | 13 Jul 2022 | 860 | 18,965 (0%) | 0% | 3.0 | 2,589 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 552 | 4,969 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 552 | 17,892 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 1,932 | 19,559 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 1,932 | 18,200 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. | 13 Apr 2022 | 860 | 17,340 (0%) | 0% | 6.1 | 5,220 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 552 | 5,521 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 552 | 16,268 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 1,933 | 16,682 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 1,933 | 21,491 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. | 13 Jan 2022 | 966 | 15,716 (0%) | 0% | 8.3 | 8,018 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 552 | 6,073 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 552 | 14,749 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 23,424 | 23,424 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 13,013 | 13,013 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 552 | 14,388 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 552 | 6,625 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. | 13 Oct 2021 | 191 | 14,197 (0%) | 0% | 10.5 | 2,015 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Other type of transaction at price $ 13.90 per share. | 13 Jul 2021 | 1,530 | 13,475 (0%) | 0% | 13.9 | 21,263 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 552 | 14,027 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 552 | 7,177 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. | 13 Jul 2021 | 191 | 13,836 (0%) | 0% | 13.5 | 2,575 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 552 | 12,136 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 552 | 7,729 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.66 per share. | 13 Apr 2021 | 191 | 11,945 (0%) | 0% | 16.7 | 3,182 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 552 | 11,811 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 552 | 8,281 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. | 13 Jan 2021 | 227 | 11,584 (0%) | 0% | 18.2 | 4,122 | Common Stock |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 103,000 | 103,000 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 8,833 | 8,833 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges